Hello Spideyboy! I like your forecasts and numbers but maybe today they are a bit optimistic. By the way what is your timeframe for Elfabrio to get half of the market? My quite limited understanding says Elfabrio's two main benefits today are immunogenicity and 2 mg/kg every four weeks regimen. "In clinical studies, 17 out of 111 of patients (16%) treated with 1 mg/kg Elfabrio every two weeks and 0 out of 30 patients treated with 2 mg/kg Elfabrio every four weeks developed treatment-induced antidrug antibodies (ADAs)." Which drug is more effective Elfabrio or Fabrazyme apparently it will be possible to say only in a few years when significant comparative statistics will be possible. Unfortunately, 2 mg/kg every four weeks regimen is not yet possible and it will probably take some time to get OK on it. Do you think a patient in the middle of the year can switch from Fabrazyme or Replagal to Elfabrio? Now it's a waiting game for a significant Fabry market uptake or BO.
Market Data 
Markets 
AI
